SCGB3A2 as a growth factor and anti-apoptotic agent
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsShioko Kimura, Reiko Kurotani
Life of this patent
Estimating the term…
Abstract
The present disclosure is generally related to methods of using the secretory protein SCGB3A2 for promoting lung development and treating lung disease. Some embodiments are, for example, methods for treating and inhibiting the development of neonatal respiratory distress. Other embodiments are methods of promoting lung development in damaged or diseased lungs. Also disclosed are methods for inhibiting lung damage due to anti-cancer agents.
Claims7
A method of promoting lung development in a fetus, comprising:
- administering a therapeutically effective amount of murine or human SCGB3A2 to a pregnant mouse or human subject, wherein administration of the SCGB3A2 to the subject results in administration of the SCGB3A2 to the fetus in the pregnant subject, and wherein the administration of the SCGB3A2 to the fetus increases lung branching morphogenesis in the fetus, thereby promoting lung development in the fetus.
A method of promoting lung development ex vivo, comprising, culturing a murine or human lung explant with an effective amount of murine or human SCGB3A2, wherein culturing the lung explant increases lung branching morphogenesis in the lung explant, thereby promoting lung development ex vivo.
Dependencies are inferred from the claim text.